Amgen Stock Forecast
NASDAQ: AMGNHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD
At close: Oct 8, 4:00 PM ET · Delayed 15 min
AMGN analyst consensus
Consensus (34 analysts)
hold
Avg. price target
$391.46-3.92%
- Strong buy 4
- Buy 8
- Hold 17
- Sell 3
- Strong sell 2
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
What analysts say
According to 34 Wall Street analysts covering Amgen (2026-10-07), 12 rate the stock a buy or strong buy, 17 rate it a hold and 5 rate it a sell or strong sell, for a consensus rating of "hold". The average 12-month price target is $391.46, with a high estimate of $500.00 and a low estimate of $225.00. The average target implies downside of 3.9% from the current price of $407.44.
The spread between the highest and lowest targets is 122.2%, a wide range that reflects significant disagreement among analysts. Price targets and ratings are the opinions of third-party analysts, not MetaCap. They are frequently revised and have a mixed track record, so treat them as one input among many for AMGN.
Summary generated from market data by MetaCap's automated system. Methodology
Rating distribution
| Rating | Analysts | Share |
|---|---|---|
| Strong buy | 4 | 12% |
| Buy | 8 | 24% |
| Hold | 17 | 50% |
| Sell | 3 | 9% |
| Strong sell | 2 | 6% |
Ratings as of 2026-10-07.
Price target scenarios
| Target | Price | vs. current |
|---|---|---|
| Low target | $225.00 | -44.78% |
| Average target | $391.46 | -3.92% |
| High target | $500.00 | +22.72% |